Liz Barrett, UroGen Pharma CEO (Photo by Steven Ferdman/Getty Images)

Uro­Gen touts long du­ra­tion of re­sponse for its blad­der can­cer chemother­a­py gel

In a Phase 3 study, pa­tients who saw a com­plete re­sponse at three months af­ter re­ceiv­ing Uro­Gen Phar­ma’s ther­a­py had an 82% chance of hav­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.